Bartonellosis Market Report 2026

The bartonellosis market size has grown rapidly in recent years. It will grow from $1.3 billion in 2025 to $1.46 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing incidence of cat scratch disease, improved diagnostic capabilities in infectious diseases, availability of antibiotic therapies, expansion of hospital diagnostic laboratories, rising clinician awareness of bartonella infections.

The bartonellosis market size is expected to see rapid growth in the next few years. It will grow to $2.24 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing development of rapid diagnostic assays, rising focus on early intervention in systemic infections, expansion of specialized infectious disease care, growing adoption of precision antibiotic regimens, increasing investment in zoonotic disease research. Major trends in the forecast period include increasing adoption of molecular diagnostic techniques, rising use of pcr-based testing, growing awareness of zoonotic infections, expansion of targeted antibiotic treatment protocols, enhanced focus on early disease identification.

The increasing occurrence of zoonotic diseases is expected to drive the growth of the bartonellosis market in the coming years. Zoonotic diseases are illnesses transmitted from animals to humans, either directly or via vectors. The rise in zoonotic disease cases is attributed to factors such as heightened human-animal interactions, environmental changes, deforestation, global travel, and cross-species pathogen transmission. Bartonellosis exemplifies zoonotic diseases by demonstrating how bacterial pathogens transmitted through animal vectors, including fleas, ticks, and lice, can infect humans, causing various clinical manifestations and underscoring the significance of understanding vector-borne disease transmission in public health. For instance, in December 2024, the European Food Safety Authority (EFSA) and European Centre for Disease Prevention and Control (ECDC), Europe-based public health authorities, reported that human campylobacteriosis cases rose to 148,181, representing a 4.3% year-over-year increase from 139,225 cases in 2022. Similarly, salmonellosis cases increased to 77,486, reflecting a 16.9% growth compared to 65,478 cases in 2022. Consequently, the rising incidence of zoonotic diseases is propelling the growth of the bartonellosis market.

Major companies operating in the Bartonellosis market are emphasizing technological innovations, such as multi-microbial phage modulation, to strengthen their competitive position. Multi-microbial phage modulation utilizes tailored phage cocktails that simultaneously target multiple intracellular pathogens, addressing co-infections that often complicate Bartonella treatment. For example, in November 2024, Biologix Center, a US-based biotechnology company, launched Induced Native Phage Cocktails aimed at patients with Bartonella and Babesia co-infections. The therapy incorporates pathogen-specific phage activation, daily adaptive dosing customized to patient microbial profiles, and improved penetration into persistent infection reservoirs. This advancement allows a holistic approach to complex co-infections, reduces reliance on traditional antibiotics, and supports precision medicine initiatives. By adopting multi-microbial phage therapy, companies are promoting personalized treatment options in the Bartonellosis market while managing the clinical validation and regulatory challenges associated with emerging biologic therapies.

In October 2024, R.E.D. Laboratories, a Belgium-based biomedical diagnostic company, formed a partnership with IGeneX Inc. to broaden access to IGeneX's advanced testing panels. This collaboration allows customers across Europe, Africa, and the Middle East to obtain IGeneX’s specialized Lyme disease and co-infection tests directly through R.E.D. Labs. IGeneX Inc. is a US-based provider of bartonellosis diagnostic test kits.

Major companies operating in the bartonellosis market are Mayo Clinic Laboratories, Northwell Health Labs, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, IDEXX Laboratories Inc., Bio-Rad Laboratories Inc., Alberta Precision Laboratories, Jiangsu BioPerfectus Technologies Co. Ltd., ARUP Laboratories, Surmodics Inc., Medical Diagnostic Laboratories LLC, Creative Biolabs, IGeneX Inc., Karius Inc., Synnovis Group LLP, Galaxy Diagnostics Inc., Gold Standard Diagnostics, Eurofins Biomnis, AMMAGENOMICS Private Limited, Ringbio.

North America was the largest region in the bartonellosis market in 2025. The regions covered in the bartonellosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bartonellosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bartonellosis market by increasing costs of imported diagnostic reagents, PCR kits, laboratory instruments, and pharmaceutical ingredients used in testing and treatment. Hospitals and diagnostic laboratories in North America and Europe are most affected due to dependence on imported molecular diagnostics, while Asia-Pacific faces higher production costs for testing supplies. These tariffs are increasing diagnostic expenses and treatment costs. However, they are also encouraging domestic diagnostic manufacturing, localized reagent production, and regional laboratory capacity expansion, improving long-term diagnostic accessibility.

The bartonellosis market research report is one of a series of new reports that provides bartonellosis market statistics, including bartonellosis industry global market size, regional shares, competitors with a bartonellosis market share, detailed bartonellosis market segments, market trends and opportunities, and any further data you may need to thrive in the bartonellosis industry. This bartonellosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bartonellosis is an infection caused by bacteria of the Bartonella genus, affecting the skin, lymph nodes, and internal organs. Prompt diagnosis and antibiotic therapy are crucial to prevent serious systemic complications and ensure effective management of the disease.

The primary forms of bartonellosis include cat scratch disease (CSD), trench fever, Bartonella endocarditis, and others. Cat scratch disease, caused by Bartonella henselae and transmitted through scratches or bites from cats, results in symptoms such as swollen lymph nodes, fever, and fatigue. Diagnosis can be made using methods like polymerase chain reaction (PCR) testing, serological testing, culture techniques, and histological analysis, while treatment involves antibiotics, antibacterial agents, and supportive care. It is utilized by various end-users, including hospitals and clinics, diagnostic laboratories, and others.

The bartonellosis market consists of revenues earned by entities by providing services such as medical consultation, symptom management, and vector control and prevention. The market value includes the value of related goods sold by the service provider or included within the service offering. The bartonellosis market includes sales of diagnostic kits, preventive products, pain relievers, and immune support supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.